Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Thalidomide has both anti-angiogenesis and antiemetic effects, and its combined use with
TAS-102 may reduce the gastrointestinal reactions associated with TAS-102, while enhancing
antitumor efficacy and reducing the side effects of chemotherapy, and its cost is
significantly lower than that of bevacizumab, which has higher pharmacoeconomics and greater
clinical research application value.